VKTX Viking Therapeutics, Inc. gains 81% Oct 16, 2017

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. Its lead clinical program includes VK0612, an orally available drug candidate for the treatment of type 2 diabetes. The company is also developing VK5211, an orally available drug candidate, which is in a Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. In addition, it is developing VK0214, a novel liver-selective thyroid hormone receptor beta agonist for lipid disorders, such as dyslipidemia and nonalcoholic steatohepatitis, as well as VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California. http://www.priceseries.com/trade/VKTX-Viking-Therapeutics-Inc-stock-gains-81-percent-a-Trade-Record-by-priceSeries-2017090720171016.html